Stock ACHV ACHIEVE LIFE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Achieve Life Sciences, Inc.

Equities

ACHV

US0044685008

Real-time Estimate Cboe BZX
Other stock markets
 09:42:34 2024-04-26 am EDT 		5-day change 1st Jan Change
4.495 USD -1.75% Intraday chart for Achieve Life Sciences, Inc. -0.22% +9.22%
Apr. 17 JonesTrading Starts Achieve Life Sciences With Buy Rating, $20 Price Target MT
Mar. 28 Transcript : Achieve Life Sciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024

Evolution of the average Target Price on Achieve Life Sciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

489faaba3094282d84e8b6.dYfgyfGsSvlvc59TBszZZoBE_yLylFin0_2uNuv9Vo8.ANTU_6DJP6A6S8wcP7i_KcRyzGSKywuQh6_IcoWsIP8ZyIytqMAtjUJe3g~719b17e772b101e1f3e32251f58527bc

Analyst Recommendations on Achieve Life Sciences, Inc.

JonesTrading Starts Achieve Life Sciences With Buy Rating, $20 Price Target MT
Oppenheimer Adjusts Achieve Life Sciences Price Target to $18 From $21, Maintains Outperform Rating MT
Lake Street Adjusts Price Target on Achieve Life Sciences to $19 From $22, Maintains Buy Rating MT
Oppenheimer Adjusts Achieve Life Sciences Price Target to $17 From $20, Maintains Outperform Rating MT
Maxim Lowers Price Target on Achieve Life Sciences to $8 From $21, Maintains Buy Rating MT
Oppenheimer Adjusts Achieve Life Sciences PT to $20 From $27 Given Difficult Current Market Conditions, Maintains Outperform Rating MT
Oppenheimer Adjusts Price Target on Achieve Life Sciences to $27 From $23, Keeps Outperform Rating MT
Achieve Life Sciences Says Its Smoking Addiction Treatment Candidate Showed Better Quit Rates Than Placebo in Phase 3 Trial MT
ACHIEVE LIFE SCIENCES : Alliance Global Partners Starts Achieve Life Sciences at Buy with $25 Price Target MT
ACHIEVE LIFE SCIENCES : Oppenheimer Initiates Coverage on Achieve Life Sciences With Outperform Rating, $23 Price Target MT
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2B Orca-1 Dose-Selection Trial CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.575 USD
Average target price
19.75 USD
Spread / Average Target
+331.69%
High Price Target
30 USD
Spread / Highest target
+555.74%
Low Price Target
10 USD
Spread / Lowest Target
+118.58%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Achieve Life Sciences, Inc.

JonesTrading Institutional Services
Oppenheimer
Lake Street
Maxim
Alliance Global Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ACHV Stock
  4. Consensus Achieve Life Sciences, Inc.